Introduction: A Paradigm Shift in Cardiovascular Medicine

Sodium-glucose co-transporter 2 (SGLT2) inhibitors were initially developed as glucose-lowering agents for type 2 diabetes, but their remarkable cardiovascular benefits have reshaped heart failure prevention strategies. Large-scale randomized controlled trials have demonstrated that these agents reduce the risk of hospitalizations for heart failure and cardiovascular death in patients with and without diabetes. This article explores the mechanisms, clinical evidence, and practical implications of using SGLT2 inhibitors in heart failure prevention, providing clinicians and researchers with a comprehensive understanding of their role in modern cardiovascular care.

Understanding SGLT2 Inhibitors: Mechanism of Action

SGLT2 inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, act on the proximal renal tubule. By selectively inhibiting the SGLT2 protein, they block approximately 90% of glucose reabsorption, leading to glycosuria and a modest reduction in blood glucose levels. The glucose-lowering effect is insulin-independent and carries a low risk of hypoglycemia. However, the cardiovascular benefits observed in trials appear to be largely independent of glycemic control, suggesting pleiotropic mechanisms that extend well beyond glucose excretion.

Renal Hemodynamic Effects

SGLT2 inhibitors reduce intraglomerular pressure by constricting afferent arterioles, thereby lowering hyperfiltration in patients with diabetes and early kidney disease. This action preserves renal function over time. The consequent reduction in glomerular pressure also decreases albuminuria, a known risk factor for heart failure progression.

Cardiac Metabolic Shifts

These agents promote a shift from glucose metabolism toward ketone body utilization and fatty acid oxidation in the heart. Ketone bodies (beta-hydroxybutyrate) serve as a more energy-efficient fuel for the failing myocardium, improving cardiac efficiency and reducing oxygen demand. This metabolic flexibility is thought to contribute to the observed reduction in heart failure events.

Diuretic and Hemodynamic Effects

SGLT2 inhibitors induce osmotic diuresis and natriuresis, lowering plasma volume and preload. Unlike traditional diuretics, the effect is sustained without causing significant electrolyte disturbances or activating the renin-angiotensin-aldosterone system. The reduction in blood pressure is modest (3–5 mm Hg systolic) but can contribute to long-term cardiovascular protection.

Anti-Inflammatory and Anti-Fibrotic Properties

Preclinical models and human biomarker studies show that SGLT2 inhibitors reduce inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha. They also inhibit cardiac fibrosis by suppressing transforming growth factor-beta signaling. These effects may reverse or slow the progression of adverse cardiac remodeling, a key feature of heart failure.

Key Clinical Trials Supporting Heart Failure Prevention

EMPA-REG OUTCOME (Empagliflozin)

The landmark EMPA-REG OUTCOME trial enrolled over 7,000 patients with type 2 diabetes and established cardiovascular disease. Empagliflozin reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14%. Notably, the risk of hospitalization for heart failure was reduced by 35%, and cardiovascular death fell by 38%. The separation of event curves occurred within months, suggesting that the benefits are not solely due to long-term glycemic control. A full description of the trial is available at the New England Journal of Medicine.

DAPA-HF (Dapagliflozin)

The DAPA-HF trial was the first to test an SGLT2 inhibitor exclusively in heart failure patients with reduced ejection fraction (HFrEF), regardless of diabetes status. Among 4,744 participants, dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26%. The benefit was consistent across all subgroups, including those without diabetes. These results, published in the New England Journal of Medicine, propelled SGLT2 inhibitors into heart failure guidelines globally.

EMPEROR-Reduced (Empagliflozin)

EMPEROR-Reduced evaluated empagliflozin in 3,730 patients with HFrEF. It found a 25% reduction in the primary endpoint of cardiovascular death or hospitalization for heart failure. The benefit was independent of baseline ejection fraction severity and diabetes status. Importantly, the trial also demonstrated a 50% reduction in the rate of decline of estimated glomerular filtration rate, reinforcing dual cardiorenal protection. Data from this study were simultaneously published in the New England Journal of Medicine.

DELIVER (Dapagliflozin) and EMPEROR-Preserved (Empagliflozin) – Heart Failure with Preserved Ejection Fraction

Historically, patients with heart failure with preserved ejection fraction (HFpEF) had limited therapeutic options. The DELIVER trial (dapagliflozin, 6,263 patients) and EMPEROR-Preserved (empagliflozin, 5,988 patients) both met their primary endpoints, demonstrating significant reductions in heart failure hospitalizations in the HFpEF population. The combined analyses from these trials have established SGLT2 inhibitors as the first class of drugs to show consistent benefit across the full spectrum of ejection fractions, from <40% to >60%. The FDA approval for dapagliflozin in HFpEF (2023) and empagliflozin (2022) underscores the clinical importance of these findings.

Integration into Heart Failure Prevention Strategies

Guideline Recommendations

Major cardiovascular societies, including the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC), have updated their guidelines to recommend SGLT2 inhibitors in the management of chronic heart failure. For HFrEF, SGLT2 inhibitors are now a cornerstone of guideline-directed medical therapy (GDMT), alongside beta-blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), and mineralocorticoid receptor antagonists (MRAs). For HFpEF, the 2023 ACC/AHA guidelines give dapagliflozin and empagliflozin a Class 2a recommendation, recognizing their role in reducing heart failure hospitalizations.

Patient Selection

SGLT2 inhibitors are suitable for most adults with heart failure, including those with type 2 diabetes, prediabetes, or normal glucose metabolism. While initial concerns involved volume depletion and genitourinary infections, careful patient selection and monitoring mitigate these risks. Absolute contraindications include a history of severe renal impairment (eGFR < 20–25 mL/min/1.73 m², depending on the agent) and a history of diabetic ketoacidosis (in diabetic patients). SGLT2 inhibitors are not recommended in patients with type 1 diabetes due to elevated ketoacidosis risk, though research is ongoing.

Combination with Existing Therapies

Because SGLT2 inhibitors exert complementary mechanisms to other heart failure therapies, they are typically added on top of existing GDMT. In the DAPA-HF and EMPEROR-Reduced trials, patients were already receiving optimal background therapy—including beta-blockers, ACE inhibitors/ARBs/ARNIs, and MRAs—and the addition of an SGLT2 inhibitor provided additive benefit. This additive effect is likely due to the unique diuretic, metabolic, and anti-remodeling properties not fully covered by other drug classes.

Safety Profile and Practical Management

Common Adverse Effects

The most frequent side effects include genital mycotic infections (particularly in uncircumcised men and premenopausal women), urinary tract infections, and volume depletion-related symptoms such as dizziness and orthostatic hypotension. Rare but serious adverse events include Fournier gangrene (necrotizing fasciitis of the perineum), diabetic ketoacidosis (even in patients with modestly elevated blood glucose), and acute kidney injury, although large meta-analyses suggest that the risk of acute kidney injury is actually reduced with SGLT2 inhibitors compared to placebo.

Laboratory Monitoring Before and During Therapy

  • Renal function: eGFR should be checked before starting therapy and periodically thereafter (e.g., every 3–6 months). Temporary discontinuation during episodes of acute illness or volume depletion is recommended.
  • Electrolytes: SGLT2 inhibitors can cause mild hyperkalemia (especially when combined with RAAS blockers) and hyponatremia. Monitoring is advisable, particularly in patients with baseline electrolyte disturbances or advanced kidney disease.
  • Hemoglobin A1c: In diabetic patients, glycemic control improves, and doses of insulin or insulin secretagogues may need to be reduced to prevent hypoglycemia.
  • Urine ketones: Consider monitoring in patients at high risk of ketoacidosis, such as those who are fasting, critically ill, or on a low-carbohydrate diet.

Drug Interactions

SGLT2 inhibitors have minimal drug-drug interactions. No clinically significant interactions with P450 enzymes or common cardiovascular drugs have been reported. However, caution is warranted when co-administering with loop diuretics due to additive volume depletion, and with insulin or sulfonylureas due to the additive risk of hypoglycemia.

Expanding Indications: Beyond Heart Failure

Chronic Kidney Disease

The CREDENCE trial (canagliflozin) and DAPA-CKD trial (dapagliflozin) established that SGLT2 inhibitors also slow the progression of chronic kidney disease, regardless of diabetes status. These agents reduce albuminuria and preserve eGFR, with cardiovascular benefits observed as a secondary outcome. The FDA and EMA have approved dapagliflozin and canagliflozin for use in chronic kidney disease, further broadening their therapeutic reach.

Primary Prevention in High-Risk Populations

While most trials enrolled patients with established heart failure or diabetes, the DECLARE-TIMI 58 trial (dapagliflozin) in patients with type 2 diabetes but without established cardiovascular disease showed a significant reduction in heart failure hospitalizations. This suggests that SGLT2 inhibitors may be considered for primary prevention in high-risk diabetic patients with multiple risk factors (hypertension, obesity, chronic kidney disease). However, guidelines currently do not recommend broad primary prevention in non-diabetic populations without established heart failure.

Acute Decompensated Heart Failure

Early initiation of SGLT2 inhibitors during hospitalization for acute heart failure is being investigated in trials such as EMPULSE (empagliflozin) and SOLOIST-WHF (sotagliflozin). Initial results indicate improved clinical outcomes and reduced rehospitalization rates. As evidence accumulates, the peri-discharge period may become a key therapeutic window for starting these agents.

Cost-Effectiveness and Access

Several pharmacoeconomic analyses have demonstrated that SGLT2 inhibitors are cost-effective in heart failure populations, primarily due to reductions in hospitalizations and mortality. In many countries, the number needed to treat (NNT) to prevent one heart failure hospitalization over 2 years is approximately 20–30. Generic formulations of some SGLT2 inhibitors are now appearing in certain markets, which will further improve affordability. For patients without insurance, patient assistance programs are often available through the manufacturers.

Special Populations

Elderly Patients

Heart failure predominantly affects older adults, and SGLT2 inhibitors have shown consistent safety and efficacy in patients aged 65 and older. However, careful monitoring for volume depletion, falls, and renal function is warranted. Starting with a lower dose (if available) and ensuring adequate oral hydration are recommended.

Patients with Advanced Chronic Kidney Disease

An eGFR below 20–25 mL/min/1.73 m² is typically a contraindication for initiating SGLT2 inhibitors, but data from DAPA-CKD and EMPA-KIDNEY suggest that benefits persist down to an eGFR of approximately 25 mL/min/1.73 m². Once initiated, the drug can often be continued until dialysis initiation, provided that the patient’s volume status and electrolytes remain stable.

Patients with Normal Ejection Fraction (HFpEF)

Given the heterogeneity of HFpEF pathophysiology, many clinicians had anticipated that SGLT2 inhibitors would fail in this population. The positive results from DELIVER and EMPEROR-Preserved have therefore been transformative. These agents are currently the only drug class with proven benefit in both HFrEF and HFpEF, making them a first-line consideration across the ejection fraction spectrum.

Mechanisms of Benefit in Non-Diabetic Patients

The fact that SGLT2 inhibitors reduce heart failure events in patients with normal glucose metabolism underscores the importance of their glucose-independent mechanisms. The following mechanisms are thought to be particularly relevant in non-diabetic individuals:

  • Hemoconcentration and erythropoiesis: SGLT2 inhibitors increase hematocrit, partly by reducing plasma volume and partly by stimulating erythropoietin secretion. Improved oxygen-carrying capacity may benefit the failing heart.
  • Reduced oxidative stress: By lowering mitochondrial reactive oxygen species production, these drugs protect the endothelium and myocardial cells.
  • Improved ventricular function: Serial echocardiographic assessments in trials have shown favorable changes in left ventricular mass, filling pressures, and ejection fraction with SGLT2 inhibitor therapy.

Future Directions and Unanswered Questions

Despite the wealth of evidence, several questions remain. Ongoing research is evaluating head-to-head comparisons among different SGLT2 inhibitors, the role of combination with finerenone (a nonsteroidal mineralocorticoid receptor antagonist) in diabetic kidney disease, and the utility of SGLT2 inhibitors in heart failure with preserved ejection fraction caused by specific etiologies such as amyloidosis or hypertrophic cardiomyopathy. Additionally, trials are underway to explore the potential benefit of SGLT2 inhibitors in patients with heart failure and acute myocardial infarction.

Another area of active investigation is the use of SGLT2 inhibitors in patients with advanced heart failure who are awaiting heart transplantation or ventricular assist device implantation. Preliminary data suggest that these drugs may improve hemodynamics and reduce the need for inotropic support, but more rigorous trials are needed.

Practical Clinical Implementation

To successfully integrate SGLT2 inhibitors into clinical practice, clinicians should start by identifying appropriate candidates (HFrEF, HFpEF, chronic kidney disease, or high-risk type 2 diabetes). Initiate therapy at standard doses (e.g., empagliflozin 10 mg daily, dapagliflozin 10 mg daily) and educate patients about potential genital infections and the importance of staying hydrated. Provide a clear plan for temporary discontinuation during acute illness (the “sick day rules”). Follow up within 1–3 months to assess tolerance, volume status, and renal function.

For patients already on diuretics, consider reducing the diuretic dose by 25–50% at initiation to minimize the risk of symptomatic hypotension. In patients with eGFR between 25 and 45 mL/min/1.73 m², monitor serum creatinine closely during the first month, as small initial declines are common and usually self-limited.

Conclusion

SGLT2 inhibitors have evolved from diabetes-specific agents to foundational therapies in heart failure prevention across the entire ejection fraction spectrum. Their unique combination of diuretic, metabolic, anti-inflammatory, and renal protective effects positions them as a pillar of modern cardiovascular pharmacotherapy. The consistent results from large, well-designed trials—empagliflozin and dapagliflozin leading the way—have prompted sweeping changes in clinical guidelines and have improved outcomes for millions of patients worldwide. As ongoing research continues to refine their use and discover new indications, SGLT2 inhibitors will undoubtedly remain at the forefront of heart failure prevention strategies for years to come.